Blocking the CD39/CD73 pathway synergizes with anti-CD20 bispecific antibody in nodal B-cell lymphoma.

ABSTRACT: Bispecific antibodies (BsAb) have emerged as a leading treatment modality in patients suffering from B-cell non-Hodgkin's lymphoma (B-NHL). However, treatment failure is common and may potentially be attributed to pre-existing or emerging T-cell exhaustion. CD39 catalyzes-together with CD73-the hydrolysis of immunogenic ATP into immunosuppressive adenosine and thus actively promotes an immunosuppressive micromilieu. Previously, we and others demonstrated that CD39⁺ T-cell subsets may have an adverse impact on the efficacy of T-cell-engaging immunotherapies. In this study, we applied an autologous ex vivo culture model of primary lymph node-derived T cells to investigate the potential of anti-CD39 or anti-CD73 blocking antibodies as T-cell enhancing combination partners of an ant

SUBMITTER: Kolbe C 

PROVIDER: S-EPMC11784132 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature